Vnitr Lek 2013, 59(7):584-586

Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs

F. Perlík

Farmakologický ústav 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. Ondřej Slanař, Ph.D.

Metabolic liver functions are significantly involved in the total clearance of a number of drugs. In liver cirrhosis the reduced drug elimination is a result of the blood flow through the liver, hepatocytes function and volume of hepatic tissue. Pharmacokinetic and pharmacodynamic changes depend on the nature and degree of hepatic impairment and on the characteristics of the dosed drug. Hepatocytes have a different extraction ability with respect to the individual drugs. The following are examples of drugs with high hepatic extraction: anodyne, propranolol, metoprolol, verapamil and lidocaine. These drugs are significantly dependent on the first passage through the liver. Intrahepatic and extrahepatic collateral blood flows significantly increase their biological availability and reduce the clearance. The reduction in hepatic clearance of drugs with low extraction coefficient, such as chlordiazepoxide, diazepam or furosemide, is a result of its own limited functional capacity to eliminate the drug. Predicting a hepatic metabolic disorder based on a common biochemical assessment of enzyme activities is not sufficient. In advanced liver cirrhosis a higher risk is demonstrated for drugs with a narrow therapeutic width. It is always necessary to take into account whether the pharmacotherapy is necessary, use small doses and cautiously monitor the patient.

Keywords: drug clearance; pharmacodynamics; pharmacokinetics; liver cirrhosis; dose adjustment

Received: March 6, 2013; Published: July 1, 2013  Show citation